Dovato ® (dolutegravir/lamivudine) – Expanded indication
August 6, 2020 - ViiV Healthcare announced the FDA approval of Dovato (dolutegravir/lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
Top